Mounjaro expected weight loss: what the trial results tell you

Step 1: the early weeks, what to realistically expect at 2.5mg and 5mg

Treatment starts at 2.5mg for the first four weeks. This pen exists to let your body adjust to tirzepatide's dual GIP and GLP-1 receptor action, not to produce dramatic weight loss. Some people do notice reduced appetite almost immediately; others feel little change at this stage beyond mild nausea that settles within days. It is one of the most common misconceptions about Mounjaro that the first pen is 'not working', the starter dose is doing exactly what it is meant to do.

At 5mg, the clinical picture starts to shift. In SURMOUNT-1, participants at 5mg (the lowest maintenance dose studied) averaged around 12.4% weight reduction by week 72. That is roughly 12 kg for a person starting at 100 kg, a clinically significant result in its own right, though lower than higher doses. If you are tolerating 5mg well and your prescriber supports titration, the trajectory tends to steepen. The timeline of how Mounjaro takes effect covers the early weeks in more detail for people at this stage.

A practical note: appetite reduction often precedes visible scale changes. Many people report eating noticeably less before their weight charts show it. Patience at this phase pays off consistently in the trial data.

Step 2: building through the middle doses, 7.5mg, 10mg and 12.5mg

The middle of the titration schedule is where the expected weight loss on Mounjaro becomes more pronounced for most people. At 10mg, SURMOUNT-1 showed an average reduction of around 14.7%, approaching 15 kg from a 100 kg starting point. At 12.5mg, results moved closer to the 15mg figures.

This phase typically spans months four through eight of treatment, and it is where the combination of reduced appetite, slower gastric emptying and lifestyle changes compounds most visibly. Physical activity becomes easier as body weight falls, which reinforces the effect further.

Not everyone reaches the higher doses. Some people achieve their clinical goals at 7.5mg or 10mg and stay there; others need the highest dose for the greatest effect. The prescriber's job is to titrate thoughtfully, not to race to 15mg. If you are curious about how individual results vary across the full Mounjaro weight loss journey, the range of real-world outcomes is discussed there alongside the trial figures.

Pricing across doses is worth understanding too, because different months carry different costs. The Mounjaro pricing page sets out the context for private treatment costs in the UK.

Step 3: at 15mg, the peak trial results and what they mean for you

The 15mg dose is where the headline figures come from. In SURMOUNT-1, participants at 15mg lost an average of 20.9% of body weight by week 72, with around a third losing 25% or more. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg (Wegovy) over 72 weeks, which is notable because Wegovy already outperforms most older medicines.

These are averages across thousands of participants. Some people lose more; some lose less. Starting BMI, how closely lifestyle guidance is followed, and whether underlying conditions affect metabolism all influence individual results. NICE's technology appraisal of tirzepatide (TA1026) reviewed this evidence base before recommending Mounjaro for use in the NHS, a bar that requires robust efficacy and safety data.

The expected weight loss with Mounjaro at 15mg is, by the trial evidence, among the largest of any licensed pharmaceutical intervention. Whether that translates into reaching a specific goal weight is a clinical question, not one that can be answered in advance. A prescriber considers your full picture (starting weight, health history, response to earlier doses) before commenting on likely outcomes for you specifically. For a broader look at setting realistic Mounjaro weight loss expectations, that page explores what the evidence means in practice.

Step 4: sustaining results and what happens if progress stalls

Weight loss on Mounjaro is not always linear. Most people see their fastest monthly losses early in treatment; the rate of loss naturally slows as body weight falls and the body adapts. This is normal physiology, not failure. Plateaus are common and usually temporary, and stalling on Mounjaro has specific, addressable causes that a prescriber can help identify.

Sustained results depend on continuing treatment alongside diet and activity. Trial data shows that people who stop tirzepatide without making lasting lifestyle changes tend to regain weight over the following months. NICE's review noted that prescribers should assess progress, if someone has lost less than 5% of their body weight after six months at the highest tolerated dose, continuing is reviewed on clinical grounds.

There are also benefits that go beyond the scale. The broader effects people report on Mounjaro include changes in blood pressure, blood sugar and appetite patterns that matter independently of weight. If you want to understand the full picture of what treatment involves before consulting, the Mounjaro: what to expect page covers daily practicalities alongside the results data.

If you are ready to find out whether Mounjaro is clinically suitable for you, start your free consultation, a GPhC-registered prescriber reviews your answers the same day.